View all news

Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference

03/14/2008

IRVINE, Calif., March 14 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion & Low Perfusion pulse oximetry, today announced that it is scheduled to present at the Citi Investment Research 5th Annual Small & Mid-Cap Conference at The Four Seasons Hotel in Las Vegas, NV on Wednesday, March 19, 2008 at 2:25 p.m. PT. Joe E. Kiani, Chairman and CEO, and Mark P. de Raad, Executive Vice President and CFO, will be presenting.

A live Web cast of the presentation will be available on the Masimo Web site at http://www.masimo.com. A replay of the Web cast will be available following the live presentation.

About Masimo: Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)) and oxygen content (SpOC(TM)) (pending FDA clearance), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and pleth variability index (PVI(TM)), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo Corporation

CONTACT: Investors, Mark P. de Raad, Executive Vice President and Chief Financial Officer, +1-949-297-7080, mderaad@masimo.com, or Media, Dana Banks, Manager, Public Relations, +1-949-297-7348, dbanks@masimo.com, both of Masimo Corporation

Web site: http://www.masimo.com

Multimedia Files:

Categories: Press Releases
View all news